Multimodal mAgnetic Resonance imaGIng in Cardiovascular Disease
MAGIC
Multimodal-MRI in Cardiovascular Diseases
1 other identifier
observational
2,000
1 country
1
Brief Summary
This single-center, prospective, observational cohort study aims to evaluate the clinical application value of multi-modal cardiovascular magnetic resonance (CMR) imaging in patients with cardiovascular diseases (CVD). While traditional imaging methods have limitations in fully evaluating myocardial tissue characteristics, multi-modal CMR offers a comprehensive, non-invasive "one-stop" assessment. It can simultaneously evaluate heart structure, function, tissue features (such as fibrosis and edema), and hemodynamics. The study plans to enroll patients with suspected or confirmed CVD. Participants will undergo a comprehensive multi-modal CMR scan (including Cine, T1/T2 mapping, Late Gadolinium Enhancement, and 4D flow sequences) as part of their evaluation. By tracking clinical outcomes, the study seeks to establish a standardized imaging assessment system to improve the early detection, accurate diagnosis, risk stratification, and prognostic prediction for various types of cardiovascular diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2026
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2026
CompletedFirst Submitted
Initial submission to the registry
May 26, 2026
CompletedFirst Posted
Study publicly available on registry
June 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
June 1, 2026
May 1, 2026
3 years
May 26, 2026
May 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Diagnostic Efficacy of Multi-modal CMR Parameters (AUC)
The Area Under the Receiver Operating Characteristic Curve (AUC) will be calculated to assess the diagnostic performance of multi-modal CMR parameters (specifically T1 mapping and extracellular volume \[ECV\]) in differentiating various types of cardiovascular diseases (e.g., ischemic vs. non-ischemic). The final clinical diagnosis based on ESC/ACC guidelines will serve as the gold standard.
Baseline (at the time of CMR scan)
Secondary Outcomes (2)
Correlation Between Imaging Parameters and Clinical Indicators
Baseline
Incidence of Major Adverse Cardiovascular Events (MACE)
Up to 3 years
Interventions
A comprehensive "one-stop" scanning protocol using 3.0T MRI scanners. The protocol includes Cine imaging, T1/T2 mapping, Late Gadolinium Enhancement (LGE), first-pass perfusion, and 4D flow sequences to evaluate cardiac structure, function, myocardial tissue characteristics, and hemodynamics.
Eligibility Criteria
The study population consists of consecutive adult patients (aged 18 years and older) who are clinically suspected or confirmed to have cardiovascular diseases (CVD), including but not limited to ischemic heart disease, non-ischemic cardiomyopathy, myocarditis, and valvular heart disease. These participants are enrolled from the Second Affiliated Hospital Zhejiang University School of Medicine. They are patients who are scheduled to undergo a multi-modal cardiac magnetic resonance (CMR) examination as part of their clinical evaluation to determine disease etiology or assess myocardial tissue characteristics.
You may qualify if:
- Aged 18 years and older, with no gender restrictions.
- Clinically suspected or confirmed cardiovascular disease (including but not limited to ischemic heart disease, non-ischemic cardiomyopathy, myocarditis, valvular disease, etc.), requiring a cardiac magnetic resonance (CMR) examination to determine the etiology or evaluate myocardial tissue characteristics.
- No contraindications to magnetic resonance examination, and able to cooperate with breath-holding instructions.
- Voluntarily participate in this study and sign a written informed consent form.
You may not qualify if:
- Absolute contraindications: Implantation of non-MRI compatible metallic foreign bodies (e.g., old pacemakers, implantable cardioverter-defibrillators \[ICD\], aneurysm clips, etc.).
- Relative contraindications: Severe claustrophobia, unable to complete the examination despite communication.
- Severe renal insufficiency.
- Special populations: Pregnant or lactating women.
- Presence of severe arrhythmias (e.g., persistent atrial fibrillation) leading to severely impaired magnetic resonance signal acquisition, rendering the image quality inadequate for diagnosis.
- Poor expected compliance: Unable to complete follow-up, or deemed unsuitable for enrollment by the investigator for other reasons.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
Related Publications (5)
谢明星, 王睿 & 张丽. 多模态影像在心脏疾病诊疗中的应用与进展. 临床心血管病杂志 36, 1071-1074 (2020).
BACKGROUNDPaiva L, Ferreira MJ, Afonso S, Donato P, Goncalves L. Cardiac T1 mapping in non-ST-segment elevation myocardial infarction: temporal changes in myocardial fibrosis. Front Cardiovasc Med. 2025 May 23;12:1563368. doi: 10.3389/fcvm.2025.1563368. eCollection 2025.
PMID: 40486822BACKGROUNDEichhorn C, Greulich S, Bucciarelli-Ducci C, Sznitman R, Kwong RY, Grani C. Multiparametric Cardiovascular Magnetic Resonance Approach in Diagnosing, Monitoring, and Prognostication of Myocarditis. JACC Cardiovasc Imaging. 2022 Jul;15(7):1325-1338. doi: 10.1016/j.jcmg.2021.11.017. Epub 2022 Jan 12.
PMID: 35592889BACKGROUND国家心血管病中心, 中国心血管健康与疾病报告编写组 & 胡盛寿. 中国心血管健康与疾病报告 2024 概要. 中国循环杂志 40, 521-559 (2025).
BACKGROUNDLeong DP, Joseph PG, McKee M, Anand SS, Teo KK, Schwalm JD, Yusuf S. Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. Circ Res. 2017 Sep 1;121(6):695-710. doi: 10.1161/CIRCRESAHA.117.311849.
PMID: 28860319BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 26, 2026
First Posted
June 1, 2026
Study Start
January 1, 2026
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 31, 2028
Last Updated
June 1, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share
The individual participant data (IPD) will not be shared because of current institutional policies and national data security regulations regarding the protection of patient privacy and human genetic resources. The data contains sensitive medical imaging information that is restricted from being transferred or shared outside the participating institution without specific governmental and ethical approvals.